Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...

Iron dysregulation contributes to oxidative stress, inflammation, and ferroptosis, driving retinal degeneration in dry AMD ...

Once an antibody latches on to a pathogen, broadly neutralizing antibodies inactivate it (as their name implies). This is ...

Investing.com -- Genenta Science (NASDAQ:GNTA) stock soared 241.8% in premarket trading Friday after announcing a strategic collaboration with ANEMOCYTE focused on off-the-shelf lentiviral vector ...

An RNAi based genetic screen and subsequent analyses reveal how dyneins and small GTPases coordinate autophagosome positioning at the ncMTOC in fat cells, advancing understanding of autophagic vesicle ...

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...

Genenta Science (NasdaqCM:GNTA) recently drew widespread attention after announcing an expanded partnership with Anemocyte, centered on advancing off-the-shelf lentiviral vector Plasmid DNA technology ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...